mediastinal irradiation. After these repeated relapses, he received Busulfan/Cytoxan as conditioning, then 24.5x10^6 CD34+ cells/kg of G-CSF mobilized PBSC from his HLA matched brother were infused. He maintained 100% donor status by VNTR for two months, then relapsed, resulting in a 20% donor/80% blast chimera, with concomitant CNS involvement. He was re-induced with the FLAM salvage regimen (Mitoxantrone -15 mg/ m2 x 4, Fludarabine -30 mg/m2 x 3, Cytosar -1 g/m2 x 3) along with G-CSF mobilized PBST from the same donor. He remained 100% donor for three months, with molecular assessment done weekly, with bone marrow free of ALL at the time of death from progressive CNS disease. The second patient was a 46 year old woman who was diagnosed with AML-M4. She underwent PBSCT while in second relapse 1.5 years after diagnosis. Conditioning was with busulfan/fludarabine/ATG followed by 5.47x10^6 G-CSF mobilized CD34+cells/Kg from an HLA-matched unrelated donor. She became 100% donor, and maintained this state for 10 months, after which she relapsed into a state of 20% donor/80% blasts. At this point she received the FLAM protocol followed by an infusion of G-CSF mobilized PBSC from the same donor. She then became 100% donor by VNTR. Our experience suggests that the FLAM protocol followed by infusion of stem cells may represent an effective treatment modality for patients who relapse after allogeneic transplantation.
Graft versus Malignancy / Minimal
Imatinib (STI571), specific inhibitor of Bcr-Abl tyrosine kinase is currently on clinical trials on interferon resistant/intolerant CML and chemioresistant Ph+ ALL patients. We report the molecular monitoring of 12 patients treated with imatinib for post-SCT relapse. Conventional karyotypong usually appreciates response to treatment but needs bone marrow aspirate and has low sensitivity. Bcr-Abl mRNA, found in most Ph+ leukemic patients, allows minimal residual disease detection by RT-PCR which needs to be quantitative to predict prognosis. Methods: We developed a real-time RT-PCR assay to quantitate Bcr-Abl transcript in blood samples using Taqman chemistry and a LightCycler (Roche). Our method, assessed in IFN-treated and allografted patients, was applied to imatinib-treated patients. The results were expressed as ratio of Bcr-Abl on PBGD. Sensitivity reached 10-5. Chimerism analysis was performed using STR-PCR, automated DNA sequencer and Genescan software. Patients: 12 patients (M/F:3/9, age:28-63, 9 CML and 3 Ph+ ALL)were molecularly serially investigated (median follow up : 7 mths, range 3 -15 mths).In the CML group, 6/9 were in hematologic relapse and chronic phase, 2/9 blastic phase and 1/9 in molecular relapse. In the ALL group, 2/3 were in hematologic relapse and 1/3 was in molecular relapse. Results: Bcr-Abl transcript level decrease was very rapid in most patients. Patients were evaluated each three mths and divided in 4 categories of transcript level decrease. A complete response was a Bcr-Abl transcript level below the PCR sensitivity level. A major response was a superior to 1 log (>10x) decrease. A partial response was an inferior to 1 log (<10x) but superior to twice (>2x) decrease. A ''no response'' was an inferior to 2x increase or decrease. An escape was a superior to 2x increase. After three months of treatment, 5 patients were in complete molecular response, 4 were in major response, 2 in partial response and 1 did not respond. After 6 months, 7 patients were evaluable. 2/7 were in complete response, 3/7 in major response, 1/7 in partial response and 1/7 escaped (ALL). Molecular date were correlated to cytogenetic data. At time of relapse, 7 patients had mixed chimerism or complete host peripheral hematopoiesis. All of them reverted to full donor chimerism or at least to mixed chimerism. Conclusion: Molecular monitoring is a powerful tool to demonstrate imatinib dramatic efficiency in post-SCT relapse of Ph+ leukemia patients.
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The value of monitoring CML and ALL patients harboring the bCR-ABL translocation by serial real-time quantitative PCR after allogeneic stem cell transplantation F. Gärtner, M. Rebelo, K. Potthoff, S. Zehbe, C. Waller, H. Bertz, J. Finke (Freiburg, D) Objectives: The bcr-abl translocation characterizes the malignant cell clone in almost all cases of chronic myeloid leukemia (CML) and in about 20% of acute lymphoblastic leukemia (ALL). Posttransplant long term surveillance in these patients requires sensitive, reliable and meaningful methods to detect potential relapse early when intervention is most successful. Here we developed a real-time quantitative reverse transcriptase PCR (RQ-PCR) assay based on TaqMan technology to quantify the bcr-abl translocation and determined its value in the follow-up of CML and ALL patients after transplantation. Methods: 39 patients with CML in first chronic phase or advanced disease and 2 patients with ALL received allogeneic bone marrow or peripheral blood stem cell transplantation from related or unrelated donors after conditioning therapy with a high dose busulfan-based regimen or a low intensity protocol comprising fludarabine, BCNU, and melphalan. Serial peripheral blood and bone marrow samples taken at various time points after transplantation were analysed by RQ-PCR. Results: The RQ-PCR assay detected up to 1 bcr-abl positive cell in a background of 10E5 normal cells. It was fast to perform, robust and highly reproducible. Correction for the varying RNA quality encountered in routine clinical samples by normalization with the housekeeping gene GAPDH (bcr-abl/GAPDH ratio) proved mandatory for meaningful quantitative results. In patients eventually relapsing, increasing bcr-abl/GAPDH ratios were observed, which preceded hematologic relapse up to 630 days. Response to treatment (e.g. by donor lymphocyte infusion) could be monitored by decreasing bcr-abl/GAPDH values. Conclusion: Serial RQ-PCR of bcr-abl should be the preferred method for the surveillance of CML and bcr-abl positive ALL patients after allogeneic transplantation. This method allows decisions based on the amount of bcr-abl transcripts and in particular on their dynamic behavior over time. Serial RQ-PCR provides a sensitive, fast, reproducible and easy-to-perform way for early detection of potential relapse with built-in control for RNA quality, ideal for routine clinical use.
P525
Minimal residual disease (MRD) monitoring with qualitative RT-PCR in chronic myeloid leukemia (CML) patients submitted to allogeneic stem cell transplantation P. Bernasconi, E.P. Alessandrino, S. Calatroni, D. Caldera, A.A. Colombo, L. Malcovati, M. Varettoni, P.M. Cavigliano, B. Rocca, M. Boni, I. Giardini, M. Caresana, M. Lazzarino (Pavia, I) The t(9;22)(q34;q11) translocation resulting in the Ph' chromosome and in the BCR-ABL rearrangement is strictly correlated with a CML diagnosis. The BCR-ABL rearrangement plays a crucial role in CML pathogenesis and its amplification through RT-PCR can be employed to monitor MRD in CML patients (pts) undergoing different therapeutic approaches. We report on 39 CML pts submitted to allogeneic transplantation at our Institution; 36 were in first chronic phase (CP) and 3 in an accelerated phase (AP). Twenty-four pts received stem cells from a sibling donor with a BUCY conditioning regimen, the remaining 12 from an unrelated donor with a CY+TBI regimen. The stem cell source was the marrow (31 cases) and peripheral blood stem cells (PBSC) (5 cases). Thirteen pts received the stem cells from a sex-mismatched donor and chimerism was checked with FISH using sex chromosome alphoid probes. Cut-off values were 0.791% in male recipients of a female donor, 0.477% in female recipient of a male donor. Six months post-transplant 12 pts had a RT-PCR positive assay. Seven of them, having received a sexmismatched transplant, were also tested for chimerism. Two, both CP, were complete chimeras and 5 (3 CP and 2 AP) were mixed chimeras. Considering these last 5 pts, the 3 CP showed a low recipient cell percentage (0.4-2.7%), while the 2 AP a recipient cell percentage reaching 86%. Basing on RT-PCR data, we decided to suspend Cyclosporin A (CsA). Both the pts experienced acute GvHD that determined a progressive lowering of recipient cell percentage and the achievement of a negative RT-PCR assay. Five pts showed at least one positive RT-PCR 6-12 months posttransplant. Three of them never relapsed, one died with a negative test, the r emaining, the one transplanted in AP and with a negative test after CsA withdrawn, experienced an extramedullary relapse. Twenty-two pts have a follow-up superior to one year: 18 cases had always had negative RT-PCR assay, one had a positive test only once and 3 had at least two positive tests. Two of these last 3 pts still have a positive RT-PCR. Our data suggest that a qualitative RT-PCR positive test within the first 6-12 months post-transplant is unable to predict disease outcome. In our experience relapse occurred only in pts transplanted in AP. Moreover a RT-PCR positive assay more than one year does not always signify impending relapse. In these pts a quantitative RT-PCR analysis is absolutely mandatory.
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Molecular methods for detection of minimal residual disease in multiple myeloma: sensitivity and specifity of real-time quantitative and nested PCR F. Tögel, N. Kröger, F. Korioth, B. Fehse, A. Zander (Hamburg, D) Multiple myeloma is characterized by malignant plasma cellinfiltration of bone marrow. Treatment with high-dose therapy results in a high rate of clinical remissions, but almost all patients ultimatively relapse. Clinical staging and detection of relapse is limited in sensitivity. Therefore, we established molecular methods based on the highly clone-specific CDR regions of the immunoglobulin VH locus for sensitive and specific detection of residual myeloma cells after bone marrow transplantation. Methods: VDJ rearrangements were identified using a set of VH primers and a JH primer. Clone specific rearrangements were detected by comparison with germline sequences. With the nested pcr approach first round amplification with the consensus primers was done followed by second amplification with myeloma specific primers. The real-time quantitative pcr was performed using a myelomaspecific forward primer in combination with a JH consensus Taqman probe and reverse primer. Results: Sensitivity was tested using dilutions of myeloma celllines into mononuclear cells. Nested PCR had a sensitivity of 10-6 and Taq-man-pcr of 10-5. Specifity was determined by testing different cell lines and patients probes. With accurate primer design and high annealing temperatures no unspecific results were observed. These results were confirmed by follow up of three patients after dosis reduced conditioning and allogeneic transplantation. One patient in clinical remission is still positive with nested-pcr, but tumor-load as measured by Taq-man pcr is lower than 0,001% myeloma cells. Conclusion: Molecular methods are a very sensitive and specific tool for follow up of myeloma patients after allogeneic transplantation. By using the quantitative approach it is possible to see kinetics of bone marrow tumor-load which can be used to guide therapeutic decisions like DLI.
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Qualitative and quantitative molecular evaluation of MRD in indolent NHL treated with high-dose therapy and rituximab S. Galimberti, F. Guerrini, F. Morabito, N. Cecconi, F. Papineschi, E. Benedetti, G. Cervetti, M. Petrini 
Supported by Ministry of Research
In order to determine if the Rituximab in association with highdose therapy could modify the molecular status of patients with indolent NHL, qualitative and quantitative sensitive molecular assays (Genescan and Real Time PCR) were performed. Thirty-two patients (2 chronic lymphocytic leukemias, 4 lymphoplasmocytic, 23 follicular and 3 mantle cell lymphomas) were enrolled in the study and monitored by the IgH, bcl1/JH and bcl2/JH rearrangement. 18 patients started CHOP /Rituximab/high-dose therapy as first line strategy and 14 at progression or relapse. Sixteen patients received 2 doses of the anti-CD20 monoclonal antibody before mobilization; 20 patients were transplanted and cases in the Rituximab arm further received 2 antibody doses after the PBSCT. 31/32 patients survived with a median follow up of 32 months. The overall response rate was 75%, with higher CR rate (81% versus 69%) and lower progression/relapse rate (19% versus 31%) in the Rituximab arm. A molecular marker was obtained at diagnosis in 66% out of patients, without significant differences between the two groups,
S124
but PCR-negativity rate of harvests resulted higher in the R-HD group than in the HD group (87% versus 56%). In the control cohort 5 cases PCR-negative before treatment harvested contaminated cells; no patients in the R -HD arm, negative at diagnosis, harvested PCR-positive precursors. Quantitative assays showed that even PCR-positive harvests had a 1-3 log reduction of MRD, resulting in < 1 neoplastic cell among 1000 cells in 14 tested cases. Interestingly, in the rituximab arm MRD <10-3 was found in 89% of patients versus 43% of those who did not receive anti-CD20 antibody. 20 patients were autotransplanted: 79% of them were PCRnegative. In accordance with Genescan PCR, Real time PCR showed the reduction of contamination in harvests and it predicted the relapse in patients not having reduction of MRD after PBSCT. All positive patients were already PCR-positive at the start of HD therapy and received contaminated precursors. No p atients receiving a PCR-negative graft resulted positive after PBSCT; only in the R -HD group 2 patients PCR-positive precociously after transplant achieved the molecular remission after 3 months. So, the present study confirms the important role of the Rituximab in the achievement of either clinical or molecular (qualitative and quantitative) remission in indolent NHL cases.
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Prognostic significance of minimal residual disease after hematopoietic stem cell transplantation B. Gruhn, R. Häfer, A. Voigt, S. Wittig, D. Fuchs, J. Hermann, F. Zintl (Jena, D) In a single-center study, we investigated the level of minimal residual disease (MRD) in a cohort of 70 children with ALL (n=30), AML (n=27), MDS (n=10), or CML (n=3) after hematopoietic stem cell transplantation (HSCT). Twelve patients underwent autologous HSCT and 58 patients received allogeneic HSCT. The donor was HLA-identical related in 32 patients and HLA-matched unrelated in 26 patients. The Wilms' tumor gene (WT1) expression was used for the detection of MRD because WT1 gene is expressed in the majority of patients with leukemia. In contrast, WT1 gene is not expressed in normal peripheral blood mononuclear cells (PBMCs) and only weakly expressed in normal bone marrow (BM) cells. We performed a quantitative nested reverse transcriptase-polymerase chain reaction to examine the level of WT1 gene expression. In a dilution experiment using 10-fold dilutions of K562 cells in PBMCs of a healthy donor, one leukemic cell could be detected in a background of 100,000 normal PBMCs using WT1 gene expression. For the present study, we followed up MRD in both BM and PB after HSCT. Analysis of paired BM and PB samples revealed that the level of MRD in BM was on average 14 times higher and paralleled that in PB. All 42 patients (60%) with continuous normal WT1 expression levels in BM and continuous undetectable WT1 expression levels in PB remained in complete remission after HSCT. In contrast, all 26 patients (37%) who suffered from hematological relapse presented with high levels of WT1 gene expression in BM and PB (P < 0.001). In 14 patients, we observed a gradual or rapid increase of WT1 expression levels before hematological relapse. The increase of WT1 expression levels occurred at a median of 4 weeks (range 1 week to 4 months) before hematological relapse. In two patients (3%), we diagnosed a molecular relapse using WT1 gene expression. In both patients, molecular remission was achieved by withdrawal of cyclosporine and by donor lymphocyte transfusion, respectively. In conclusion, quantitative analysis of WT1 gene expression is a valuable tool for monitoring of MRD in patients with ALL, AML, CML, and MDS after HSCT. In addition, this approach is very useful for early diagnosis and treatment of molecular relapse after HSCT.
P529 Multicentric analysis of hematopoietic chimerism

D. Bories, L. Gebuhrer, M. Bois, N. Contentin, F. Comeau, G. Semana, J.F Eliaou for the French Working Group on Hematopoietic Chimerism
Hematopoietic chimerism analysis has been emphasized in order to evaluate donor cell engraftment in allogeneic hematopoietic stem cell transplantation and to adapt immunosuppressive or cell therapy. Full donor or persistent mixed chimerism is essential for sustained engraftment and prevention of relapse. Precise analysis of chimerism, especially in multicentric trials, requires comparaison of methodological approaches and data reports. The French working group on hematopoietic chimerism was first composed of 7 labortories and performed comparison of technical protocols and quality control exchange. In 5 laboratories, chimerism was analysed by analysed by competitive PCR with a panel of STRs on isolated cell populations followed by semiquantitation using automated DNA sequencer and Genescan software (Appied Biosystems). One laboratory used non radioactive hybridization od PCR amplified VNTRs. Absolute chimerism quantitation was performed by real time PCR amplification of sequence specific polymorphisms in 1 laboratory using Taqman probes and ABIprism 7700 Sequence Detection System (Applied Biosystems). Quality control exchange samples were composed of 4 mixes each containing a known ratio of recipient and donor's DNAs. As shown in figure, evaluation of chimerism was concordant between laboratories with a coefficient of variation not exceeding 25%. Our data stress the usefulness of quality control exchanges, and the necessity to pursue our work of protocol standardization including nucleic acid extraction and cell sorting protocols.
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Graft-versus-leukemia effect after hematopoietic stem-cell transplantation with unrelated donors
M. Remberger, J. Mattsson, P. Hentschke, J. Aschan, L. Barkholt, S. Lee, N. Naseh, J. Svennilson, O. Ringdén (Stockholm, S) Background: Graft-versus-host disease (GVHD) and leukemia relapse are the major obstacle to success in haematopoietic stemcell transplantation (HSCT). However, GVHD is accompanied with a graft-versus-leukemia (GVL) effect, resulting in a lower incidence of leukemia relapse and a better leukemia-free survival among patients with GVHD. This GVL effect has been evaluated extensively in the HLA-identical sibling donor situation, but not when using unrelated donors. Aim of study. To evaluate risk factors for relapse and the GVL effect in unrelated donor HSCT. Patients: Two hundred and fourteen patients with a hematological malignancy underwent HSCT with an unrelated donor at Huddinge University hospital between May 1991 and June 2001. One hundred and eighty-five of these patients survived more than 90 days and were evaluable for relapse. Diagnoses were AML 44, ALL 56, CML 64 and other malignancies 21. 95 were in first CR/CP and 90 in later stages. A majority (86%) of the patients had a HLA-A, -B and -DR matched donor. Conditioning consisted of total body irradiation and cyclophosphamide and GVHD prophylaxis of cyclosporine and methotrexate in a majority of the patients. All patients received anti-thymocyte globulin as part of pre-transplant conditioning. Stem-cell source were peripheral blood in 46 cases and bone marrow in 139. After transplantation, G-CSF was given to 84% of the patients. Results: In the multivariate risk-factor analysis for relapse we found that high-risk disease (RR 2.20, CI 1.25-3.90, p=0.006), acute GVHD 0 -I (RR 3.00, CI 1.30-6.96, p=0.012) and ALL diagnose (RR 1.97, CI 1.16-3.35, p=0.012) were independent risk factors for relapse after HSCT with unrelated donors. The strongest anti-leukemia effect was found in patients with acute GVHD grade II, independent of chronic GVHD. Relapse incidence in patients with acute GVHD grade II were 18% compared to 46% in those with no or grade I (p=0.039). In patients with and without chronic GVHD, the incidences of relapse were 36% and 44% (p=0.03). Conclusion: Risk factors for relapse after HSCT with unrelated donors were: Acute lymphoid leukemia, disease stage beyond CR1/CP1 and no or mild acute GVHD. The strongest antileukemia effect was seen in patients with acute GVHD grade II.
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Treatment of malignant diseases by up-regulation of antitumor responses and down-regulation of anti-host responses
S. Slavin, M. Shapira, I. Silberman, I. Resnick, R. Or (Jerusalem, IL) Alloreactive donor lymphocytes (T, not excluding NK and NKT cells) represent the major therapeutic component of the bone marrow transplant (BMT) procedure. We hypothesized that improved outcome may be accomplished by reduced intensity conditioning, focusing on induction of host-versus-graft tolerance following non-myeloablative stem cell transplantation (NST), followed by induction of graft-vs-tumor (GVT) effects by donor lymphocytes. Using a murine model of B cell leukemia/lymphoma (BCL1) and metastatic breast cancer (4TI) in BALB/c recipients, we could show that eradication of malignancy can be best accomplished by immune donor lymphocytes (IDL) under conditions where naïve lymphocytes are ineffective. Interestingly, IDL resulted in reduced anti-host responses. Whereas survival of BALB/c mice inoculated with BCL1 was <28 days, survival of mice receiving 20x10^6 immune donor lymphocytes was 95% with only 1/20 mice developing leukemia. Similarly, whereas all recipients of 12 metastatic 4TI cells injected intravenously or intraportally developed extensive metastases, none of secondary recipients of 20x10^6 IDL showed evidence of pulmonary or hepatic metastases, respectively and all 12 of adoptive recipients of lung cells obtained from treated mice survived >250 days. Clonogenic assays of liver cells from recipients of syngeneic or allogeneic lymphocytes confirmed GVT effects. By combining nonmyeloablative conditioning for induction of BALB/c vs C57BL/6 transplantation tolerance based on deletion of alloreactive cells with Cytoxan 200mg/Kg and treatment with IDL, 90% of mice were cured with no GVHD, as compared with no survival among 12 controls treated with naïve donor lymphocytes. Proof of principle was documented in a patient with relapsed CML resistant to BMT and DLI who responded to IDL against parental alloantigens and alpha-interferon, with continuous molecular remission (>9 years). More recently, we have pioneered in vivo immunization of donor lymphocytes with dendritic cells pulsed with tumor antigens. In conclusion, better and safer immunotherapy of cancer may involve NST and cell therapy with IDL.
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Graft versus leukemia effect in pediatric stem cell recipients Å. Gustafsson Jernberg, M. Remberger, O. Ringden, J. Winiarski (Stockholm, S) Objectives: In paediatric patients with leukaemic disease treated with stem cell transplantation (SCT), the major cause of treatment failure and death is relapse of the leukaemia. A graft versusleukaemia (GVL) effect in humans has been proposed, and acute and chronic graft-versus -host disease (GVHD) have been presented as favourable when evaluating leukaemia-free survival. The aim with the present study was to examine whether a GVL effect also is present in a paediatric setting and to relate it to the occurrence of GVHD. Methods: A total of 181 children with leukaemia, who had undergone treatment with SCT at Huddinge Hospital, were retrospectively evaluated. Out of these, 112 children had ALL, 57 AML and 12 CML. The median age was 9 years (range: 0,5-17) and the median time of follow up was 7,5 years. The graft was obtained from an unrelated donor in 51 of the cases. Results: The 5-year probability of survival was 52%,while the 5-year probability of relapse was 41 %. Forty of the sixty relapses occurred within the first year post SCT. In a Cox regression model, acute GVHD grade II-IV and chronic GVHD were independent predictors of relapse, with a relative risk of 0,43 ( 95% CI 0,18-1.00) and 0,39 (95% CI 0,22-0,78), respectively. In terms of death, chronic GVHD remained an independent predictor with a relative risk of 0,42 (95% CI 0,22-0,78) Figure; Patients with chronicGVHD had a significantly better survival than those without chronic GVHD, p = 0,013 Conclusion: Both acute GVHD grade II-IV and chronic GVHD were shown to be independently associated with a lower risk of relapse post SCT. Moreover chronic GVHD remained an independent determinant for post SCT survival. This supports the assumptions that there is a GVL effect also in SCT of childhood leukaemia which is related to the occurrence of chronic GVHD. 
Results: No early toxicities were observed and fast engraftment with complete donor chimerism could be documented. A few days after transplantation the right tonsil had to be removed because of progressive enlargement. Tissue sections identified the tumor as metastasis of the known renal cell carcinoma. 26 days after transplantation grade II -III graft-versus-host disease (GVHD) developed and was treated with steroids. Over the following six months pulmonary metastatic lesions disappeared completely whereas the subcutaneous nodules increase in size and several metastatic lesions of the scalp developed. Tissue sections of these lesions showed only few infiltrating CD3+ T cells. Conclusion: This case illustrates that although allogeneic immunotherapy after hematopoietic stem cell transplantation can be effective in renal cell carcinoma, its efficacy might be depending on the anatomic site of the metastases in individual patients. Similar to the experiences in leukemia patients relapsing in extramedullary sites one might speculate that subcutaneous lesion could not be attacked by donor T cells to the same extent as the lung metastases.
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Use of donor leukocyte infusion (DLI) for the treatment of relapse after related allogeneic myeloablative or nonmyeloablative stem cell transplantations: analyzis of toxicity and efficacy A. Michallet, A. Thiébaut, F. Nicolini, C. Audigier-Valette, C. Vigouroux, Q. Le, D. Fiére, M. Michallet (Lyon, F) DLI for relapse after allogeneic stem cell transplantation (Allo-SCT) demonstrated its efficacy in terms of eradication of the malignant clone. Non-myeloablative allogeneic stem cell transplantation (Allo-NSCT) is a new promising therapeutic approach, although attaining complete chimerism seems more difficult and often requires DLI. We retrospectively analyzed 2 groups of patients: DLI for relapse after conventional Allo-SCT (group 1) or DLI in the context of Allo-NSCT (group 2). 30 patients were studied in group 1: 19 males, 11 females, median age: 34 years (17-47). There were 14 CML and 16 AL patients. In group 2, 39 patients were analysed: 27 males, 12 females, median age: 42 (18-62), 8 AL, 4 Chronic leukemias, 12 MM and 12 lymphomas. Chimerism were analyzed according to the semi-quantitative VNTR technique. In group 1, we observed 10 cytogenetical responses for CML and 3 CR for AL. Median number of DLI necessary to obtain a response was 2. Median delay observed between 2 DLI was 1.5 months and median dose was 7.107 CD3+/Kg. 20/30 patients only could be analysed for chimerism status. We observed 6 complete and 14 mixed chimerisms. Median number of DLI necessary to obtain complete chimerism was 2, and the delay was 3.5 months (0.25-13.2). We observed 5 acute GVHD (1 grade I, 2 grade II and 2 grade IV) and 3 chronic GVHD. GVHD after DLI appeared after median delay of 2.2 months (1-5.6). In group 2, we observed 5 CR (lymphomas and AL) and 3 PR (MM). 10/39 patients could be analysed for chimerism status. We observed 6 complete chimerisms among 10 patients. Median number of DLI necessary to obtain complete chimerism was 1.5, and median delay was 2.5 months. In this group, 3 patients, developed acute GVHD (1 grade I, 1 grade III and 1 grade IV), and no chronic GVHD occured. Median delay between DLI and appearance of acute GVHD was 1 month. Statistical analysis didn't show any difference between the 2 groups in terms of response (p=0.8) and development of acute GVHD (p=0.7). However, DLI following Allo-NSCT converted faster patients to complete chimerism, without significant increase of GVHD incidence (p=0.08).
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The importance of patient and donor CMV status in unrelated stem cell transplantation
B.E. Shaw, A.L. Pay, M.N. Potter, P. Travers, N. Mayor, H.G. Prentice, S.G.E. Marsh, J.A. Madrigal (London, UK)
Patient and donor CMV status prior to unrelated stem cell transplantation are considered to be important factors affecting outcome. It has been reported in both a T cell depleted and T replete setting that patient seropositivity is associated with worse overall survival. Reports of the impact of donor CMV status and patient/donor CMV combinations are contradictory and confusing. We have studied the effects of CMV in a cohort of 218 unrelated transplants, where donors were provided by the Anthony Nolan Trust, with well characterized high resolution tissue typing to allele level. Of the donors provided 25% were CMV positive and 27% of the patients in this cohort were CMV positive. In 59% of the transplants both donor and recipient were CMV negative, in 11% both were positive, in 16% the patient was positive and donor negative and in 14% patient was negative and donor positive. We found a significant survival advantage in patients who were CMV negative (p=0.0164), irrespective of the donor CMV status. In multivariate analysis this result remained significant with a hazard ratio of 1.8 (1.1, 2.9; p=0.01). There was no significant difference in the incidence or severity of acute or chronic graft versus host disease (cGVHD) between any of the groups. However patients who were CMV positive had a significantly increased chance of relapse (p=0.0049), once again irrespective of the donor CMV status. In multivariate analysis this result remained significant with an hazard ratio of 2.2 (1.2,4.1; p=0.01). CMV negative patients who had CMV positive donors appeared to be protected from relapse. Donor CMV positivity was associated with a lower incidence of chronic graft versus host disease (p=0.0443). This remained a significant factor in multivariate analysis with a hazard ratio of 0.4 (0.1, 0.9; p=0.02). The presence of chronic graft versus host disease conferred a survival advantage, in this largely T cell depleted cohort of patients, with a hazard ratio of 0.3 (0.17,0.56; p=0.00). Therefore while donor CMV seropositivity protects from relapse, this is balanced by a decrease in cGVHD which would tend to increase relapse; the net effect is no alteration in overall survival. We conclude that in a CMV positive patient, donor CMV status does not alter outcome, however in a CMV negative patient, the consequences of donor status should be considered for the individual patient.
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The immunosuppressive impact of idarubicine in the conditioning regimen before partially T-cell depleted allogeneic SCT in patients with chronic myeloid leukemia
N. Schaap, A. Schattenberg, Z. Kolen, F. Preijers, E. van de Wiel van Kemenade, F. Maas, M. Hillegers, A. Pennings, T. de Witte (Nijmegen, NL)
Eighty-nine patients (pts) were transplanted for CML-CP1 with Tcell depleted (counterflow centrifugation) stem cell g rafts from HLA-identical siblings. Nineteen pts were conditioned with cyclophosphamide ( 2x 60 mg/kg) and TBI (2 x 4.5 Gy) and in 70 pts the conditioning regimen was intensified by the addition of Idarubicine (Ida) 42 mg/m2. The 5 -year probability (prob.) of hematological and/or cytogenetic relapse was 70% in the standard conditioned pts. The introduction of Ida in the conditioning regimen resulted in a significantly (p=0.002) lower 5-year prob. of relapse (41%). The addition of Ida correlated with significantly more acute GVHD. (p=0.017). Transplant related mortality was not influenced by Ida. The 5-year prob. of current leukemia-free survival defined as survival in first or second (after therapeutic DLI) remission were identical for both conditioning regimens (64% and 63%, respectively). Ten pts were randomized between the standard or the intensified conditioning. In these 10 pts chimerism was monitored frequently in highly purified subsets of PBMC's and granulocytes using a newly developed real-time quantitative PCR of single nucleotide polymorphisms. Pts conditioned with Ida developed significantly earlier (median, 6 versus 12 months) complete donor chimerism in the T-lymphoid (CD3+/CD4+ and CD3+/CD8+ ) subsets compared to the patients conditioned with the standard regimen (p=0.017). In the intensified conditioned pts this immunosuppressive effect is additionally demonstrated by significantly lower (p=0.028) percentages of autologous Tlymphocytes in the first 6 months after SCT. The addition of Ida in the conditioning had no influence on the time to reach complete donor chimerism in the investigated non T-lymphoid subsets. We conclude that the addition of Ida to the conditioning regimen in the setting of allogeneic T -cell depleted SCT resulted in a rapid clearance of autologous T -lymphocytes that may explain the increased prob. of acute GVHD and the decreased relapse rates. However in pts suffering from CML, the addition of Ida to the conditioning regimen did not influence current leukemia-free survival due to the impact of therapeutic DLI. In pts transplanted for hematological malignancies that do not respond well to DLI for treatment of relapse this observation may have consequences for the conditioning regimens before T-cell depleted SCT.
P537 Incidence and features of large granular lymphocytes (LGL) following allogeneic stem cell transplantation: a long-term analysis
M. Mohty, C. Faucher, N. Vey, C. Chabannon, D. Sainty, C. Arnoulet, B. Gaugler, J. Gastaut, D. Maraninchi, D. Olive, D. Blaise (Marseille, F) Large granular lymphocyte (LGL) proliferation follows a chronic course during which major features are cytopenia and immune abnormalities. Persistently elevated numbers of LGL have been shown to be increased in few cases after allogeneic stem cell transplantation (allo-SCT). In the present report, we undertook a retrospective analysis of all LGL cases occurring following allo-SCT in a large cohort of 201 patients. The aim of the study was to determine clinical and biological features associated with LGL expansion following allo-SCT. Six cases could be documented over a long follow-up period of seven years. We demonstrate that LGL expansion occurs more frequently following a reduced preparative regimen (4 cases), as compared to conventional myeloablative regimens (2 cases) (incidence 8.2% vs. 1.3%, P=0.04). Expansion of LGL was seen between 3 and 15 months following allo-SCT. Hematopoiesis, with mild to severe cytopenia, was a privileged target for LGL. Different autoimmune manifestations like polyarthritis and hypergammaglobulinemia were also observed. LGL proliferation was observed in the context of chronic antigenic stimulation associated with recurrent viral infections especially CMV. Moreover, 5 patients out of these 6 high risk patients, achieved a long term complete remission concomitant or following LGL expansion. These data suggest that LGL are a subset with the properties of effector lymphocytes which may represent an important component of the graft versus tumor effect.
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Hematogones in the healthy bone marrow G. Pricolo, L. Stani, A. Prudenzano, S. De Pasquale, S. Scafa, P. Mazza (Taranto, I) Multiparameter flow cytometry may be used to detect minimal residual disease in acute leukemia because leukemic cells often display aberrant phenotypes when compared to normal cells. One limitation of this approach in B -lineage Acute Lymphoblastic Leukemia ( B-ALL ) is that rare subpopulations of normal marrow B lymphoid cells , expressing immunophenotypes typically found in B-ALL, were sought by multiparameter flow cytometry in the marrow of both children and adults after autologus and allogeneic transplantation or conventional chemotherapy for acute leukemia. These cells, in some patients, may account to greater than 50% of bone marrow cells, creating a picture that can be confused with Acute Lymphoblastic Leukemia (ALL) or metastatic tumor. Although originally called hematogones (HGs), a variety of other names have been proposed for these unique cells. The clinical significance of expanded HGs has not been resolved, and the biologic features are incompletely described. This study included the immunophenotypic characterization of different precursor and mature B cell populations in the bone marrow samples taken from 15 healthy individuals, who served as bone marrow donors. The samples were analyzed with different antibody combinations using four-colour and CD45 -gating strategies: CD10FITC/CD34PE/CD45PerCP/CD19APC; D20FITC/CD34PE/CD45PerCP/CD19APC ; CD22FITC/CD34PE/CD45PerCP/CD19APC; HLA-DR FITC/CD34PE/CD45PerCP/CD19APC ; sKappa FITC/sLambda PE/CD45PerCP/CD19/APC ; cyKappa FITC/cyLambda PE/CD45PerCP/CD19/APC. In 13/15 samples two immature CD19+ subpopulations with different SSClog/CD45 distribution on the cytogram and coexpressing B cell-associated antigens were identified: CD34+/CD19+/CD22dim+/CD10dim+/HLA-DR+/CD45dim CD19+/CD22dim+/CD10dim+/HLA-DR+/CD45dim Representing 0.2% ( 0.1-0.7 ) and 0.68% ( 0.2-1.5 ) of the total BM nucleated cells, respectively. The patterns of antigen expression were very reproducible in all 13 samples and were not found to be age related. These two populations never merged either with mature CD19+ population, or ALL-B blast region. We conclude that Hematogones aren't an unusual finding in the healthy bone marrow and their particularly SSClog/CD45 distribution allows the discrimination between normal and malignant precursor B-cells and can therefore be used for MRD studies.
Additional abstracts to this topic
Early immunotherapy to reverse mixed chimerism in children with malignancies after allogeneic stem cell transplantation (alloSCT) D. Turkiewicz, E. Gorczynska, J. Toporski, K. Kalwak, B. Rybka, R. Ryczan, J. Boguslawska-Jaworska, A. Chybicka (Wroclaw, PL) Mixed chimersim (MC) after alloSCT is associated with high risk of relapse or graft rejection. To prevent these life-threatening complications immunotherapy was initiated in patients with autologous cells detected after transplantation. Patients: Immunotherapy was started in 12 children with malignancies (ALL 7 AML 4 CGL 1) who developed MC after alloSCT. Eight children received hematopoietic cells from HLA id siblings (MSD) and 4 from mismatched relatives (MFD). Busulfanbased conditioning regimens were used. GvHD prophylaxis consisted of CsA +/-MP (MSD), T-cell depletion only (MFD) or CsA+MTX+MP for a patient transplanted from MFD with unmanipulated graft. Methods: Hematopoietic chimerism was monitored in PB MNCs and BM by semiquantitative fluorescent VNTR-PCR assay. MNCs were isolated by density gradient centrifugation. In 7 patients on CsA prophylaxis, when stable or increasing MC was detected in 2 consecutive assessments with no signs of GvHD, CsA was withdrawn. If no GvHD appeared and no decrease in autologous DNA was detected after CsA had been tapered, patients were scheduled for DLI. Patients with MC after T cell depleted transplants received T-cell add-backs as front-line therapy. In one patient (UPN 223) after alloSCT from MSD on CsA+MP prophylaxis, steroids were tapered and CsA level decreased. Results: Patient UPN 223 responded to withdrawal of steroids and converted to complete chimera (CC) with no signs of GvHD. Four patients responded to cessation of CsA and converted to CC. Two of them developed grade II and grade III aGvHD, which responded to reintroduction of CsA. One experienced CNS relapse while being CC in both BM and PB. Among 3 patients who failed to respond to CsA withdrawal, 2 subsequently relapsed. One refused further treatment and died in relapse. One received chemotherapy followed by DLI with transient response and died due to disease progression. One patient received DLI and gradually eliminated autologous cells, remains in CR with no symptoms of GvHD. Three patients developed increasing MC after transplantation of TCD graft. Two did not respond to T-cell add-backs and finally rejected the graft. One rapidly eliminated autologous cells, converted to CC and developed grade III aGvHD with good response to steroids Conclusion: Our limited data suggest that chimerism-guided immunotherapy may eradicate residual host cells. Further studies are required to prove clinical efficacy of this therapeutic approach.
Role of chimerism in prevention and/or treatment of posttransplant leukemia relapse in children P. Sedlaeek, R. Formankova, J. Stary, L. Krskova, H. Oihova, L. Ramkova, J. Moravcova (Prague, CZ) We present the role of hematopoietic chimerism(HC) in prediction of post-transplant outcome and our experience with adoptive immunotherapy (AI) in prevention and treatment of leukemia relapse after HSCT. Methods: Between 1/1997 and 12/2000 43 patients(ALL 16,AML 15,CML 5,MDS 6,JMML 3,CMML 1) underwent 46 unmanipulated allogeneic HSCT from identical siblings (23) or unrelated donors (23). We have analyzed chimerism in PB samples using PCR of VNTR in 44 evaluable follow-ups. AI was used in 11 pts (ALL 3,AML 5,CML 2,JMML 1/2x). The treatment was initiated on the basis of increasing mixed chimerism (inMC;7), in molecular relapse (1) or in hematological relapse (4). Withdrawal of immunosuppression was performed in 9 patients, 5 of them received also donor lymphocyte infusion (DLI) and in 3 DLI was applied as a front-line therapy. AI was combined with chemotherapy in 2 children. CD3+ doses varied between 1x105 and 2,4x108/kg bw according to type of donor and indication. Results: Complete donor chimerism(CC) after day+28 was documented in 25/44 follow-ups. Mixed chimerism(MC) after D+28 was found in 19/44 follow-ups. Transient MC(trMC) was detected in 7, inMC in 12 follow-ups. Transplant related mortality day+100 was 7/25 in CC and 1/19 in MC group; 36 patients were evaluable for relapse free survival(RFS). At a median follow-up of 19 months (2-51 months) RFS for CC group was 17/18, MC group was 7/18. Hematological relapse was documented in 1/7 children with trMC, in 1 patient molecular relapse was detected and AI was started before the appearance of trMC. InMC was followed by hematological relapse in 9/12 follow-ups, 3/12 patients with inMC responded to AI and re-achieved CC. Complete response to AI was defined as sustained recurrence of CC and CCR was documented in 4/12 children (1 AML,2 CML,1 JMML) at a median follow-up of 30 months (15 -40 months), 1 patient (ALL) achieved CC but died due to severe GVHD. 3 patients (2 AML,1 JMML) showed transient decrease or disappearance of MC and developed relapse subsequently 8, 9 and 20 months after intervention. No response was seen in 4/12 follow-ups (2 ALL,2 AML). Conclusions: Frequent monitoring of HC allows identification of patients with high risk for hematological more than extramedulary relapse and therefore indicated for AI. In some children with leukemia methods of AI allow to prevent or treat posttransplant relapse. This work was supported by grants IGA-MZ ÈR NC 6512-3 and IGA-MZ ÈR NC 5902-3.
Three different methods for detection of minimal residual disease in neuroblastoma
A. Vicha, D. Sumerauer, J. Malis, T. Eckschlager, J. Cinatl (Prague, CZ; Frankfurt, D) Aim: Detection of neuroblastoma cells in bone marrow and circulating neuroblasts during treatment may predict clinical outcome and correlate with tumor recurrence.
The aim of study was to confirm usability of methods for detection of minimal residual disease (MRD). We evaluated methods per these criteria: sensitivity, speed and cost. Recommendations for quantitation of minimal residual disease in multiple myeloma T. Rasmussen, H. E Johnsen (Herlev, DK) Objective: Changes in the level of minimal residual disease (MRD) in patients with multiple myeloma (MM) might be predictive of relapse. However, the level of MRD in MM may span 6 logs, and methods with high sensitivity and reproducibility over a broad dynamic range is thus necessary for quantitation of MRD in MM. We have tested flow cytometry, patient-specific real-time PCR and patient-specific nested RT-PCR combined with limiting dilution statistics for quantitation of MRD in MM patients. Materials and Methods: Nine patients were included in the study. All patients received an induction program of three cycles of VAD (vincristine, doxorubicin and dexamethasone), followed by highdose cyclophosphamide (4g/m2) and granulocyte colonystimulating factor (G-CSF), followed by peripheral blood stem cell (PBSC) harvest and finally high-dose therapy with melphalan (200 mg/m2), followed by PBSC transplantation of a minimum of 2 x 108 CD34+ cells/kg total weight. The flow cytometric method used CD56, CD28 and CD117 as ''tumor specific antigens'' whereas the PCR based methods used allele-specific oligonucleotides (ASO) corresponding to the complementary determining region 3 (CDR3) of the rearranged immunoglobulin heavy chain gene (IgH). Results: The sensitivity was 1:104, 1:105,1:106 for flow cytometry, patient-specific real-time PCR and patient-specific nested RT-PCR, respectively. The tumor burden determined in BM by the three methods was in relatively good agreement with values obtained by microscopic examination and the measured serum Mprotein. Consistently low levels of clonal cells were seen in patients considered in complete remission and increased levels were seen at relapse in both BM and PB. BM and PB samples were tested positive at all time-points using PCR based methods whereas 1/3 of blood samples were negative during treatment when measured by flow cytometry. Conclusion: This study shows that different quantitative methods can monitor MRD in patients considered to be in complete remission and offers an opportunity to enhance our understanding with regard to the clinical importance of residual malignant cells. PCR based methods has high sensitivity but are time-consuming and applicable to only 70% of patients. Flow cytometry has a lower sensitivity but allows a fast evaluation of all patients.
Establishment of stable continuous molecular remission by immunotherapy in combination with STI-571 in a patient with molecular relapse of BCR/ABL positive ALL after allogeneic stem cell transplantation E. Prinz, H. Scheuringer, H.T. Greinix, P. Kalhs, N. Worel, W. Sperr, W. Rabitsch, M. Mitterbauer, A. Schulenburg, K. Lechner, F. Keil (Vienna, A) We report an 39 year old male patient diagnosed with bcr/ablpositive ALL. After induction therapy according to the Hölzer-protocol he achieved a complete remission but experienced relapse 3 months later and received an allograft from his HLAidentical sibling without reinduction chemotherapy. Conditioning therapy consisted of cyclophospamide (120 mg/kg b.w.) and fractionated total body irradiation of 13.2 Gy. After infusion of 7.9 x 10^6 CD34+ cells obtained from the peripheral blood from his HLA identical brother he was treated with standard immunosuppressive therapy (cyclosporine A and methotrexate). Posttransplant course was uneventful and one month after allogeneic SCT he achieved hematological, cytogenetic and molecular complete remission. The patient remained bcr/abl-negative in consecutive molecular analyses for 12 weeks. Seven weeks after SCT he presented with bronchiolitis obliterans organizing pneumonia (BOOP) and steroid therapy was mandatory for 5 weeks. Two weeks after cessation of steroid therapy the patient suffered molecular relapse defined as 3 bcr/abl positive probes in RT-PCR in course. The detection limit of RT-PCR is 1 bcr/abl positive cell in 100 000 cells. Thus, immunosuppressive therapy was stopped and the patient received STI-571 (400 mg/d) and a reinfusion of alloreactive T cells (1.3 x 10^3/kg b.w. CD3+ donor cells).One week later he became bcr/abl negative and is in complete molecular remission for 12 weeks. The interval between molecular and haematological relapse in patients with ALL after allogeneic SCT is short and survival is poor. Molecular remissions induced by DLI habe been reported, but even an effective stimulation of donor T cells may not be able to suppress the rapid expansion of the leukemic clone. Treatment with STI-571 may result in rapid and specific suppression of the bcr/abl positive clone. The antileukemic effect of alloreactive donor cells is observed between 6 and 32 weeks. Thus the combination of both STI and DLI may result in improved outcome of patients relapsing with bcr/abl positive ALL.
Infections Viral
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Virus surveillance in pediatric HSCT patients: single center experience W. Ebell, A. Reip, J. Kuehl, A. Heiden, S. Voigt, G. Gaedicke, H. Meisel (Berlin, D) Intensive PCR based viral screening was performed during the course of allogeneic transplants in 53 children with the following characteristics. Donor: MRD 22, MMRD 6, MUD 25. Diagnosis: leukemias 35, inborn errors 16, SAA 2. Age: recipient 5,5 (1-19) years, donor 15,7 (1-63) years. CMV-seropos.: recipients 63 %, donors 40 %. EBV seropos. : recipients 74 %, donors 88 %. HHV-6 seropos. : recipients 55 %, donors 44 %. Adenovirus seropos. : recipient 92 %, donors 63 %. Results : During the early post transplant course 34 % of the patients became positive for CMV, 14 % for EBV, 13 % for HHV-6, and 36 % for adenovirus. There were only 22 % of patients without proof of any virus. 48 % of patients showed at least 1 virus, 13 % 2 viruses, and 15 % 3 and more viruses. In multiple viral carriers the treatment related mortality went up from 10 % to 22 %, aGVHD II from 18 % to 44 %, aGVHD III-IV from 0 % to 22 %, and severe chronic GVHD from 0 % to 56 %. The most often detected virus was the adenovirus which was highly associated with critical morbidity in 22 % of the positive patients. Comparing such adenovirus positive with negative transplant recipients severe aGVHD III-IV occurred in 21 % compared to 3 %, severe cGVHD in 32 % compared to 6 %, severe intestinal involvement in 37 % compared to 6 %, and severe liver involvement in 32 % compared to 3 %. The virus was most often detected in stool followed by urine and nasal wash/BAL. All serotypes could be demonstrated. Patients receiving ATG were at higher risk than patients without ATG. Conclusions: Treatment related mortality and morbidity in allogeneic transplants is highly associated with the detection of multiple viruses. Adenovirus infections/ reactivations belong to the most critical events during such transplants. Pre-emptive treatment strategies have to consider the critical virus spectrum and multiplicity, and the ideal therapy to control all of these viruses at the same time without major side effects still have to be demonstrated.
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The role of polyomavirus in the development of posttransplant haemorrhagic cystitis C. Diaz De Heredia, T. Olive, C. Polo, J. Perez, I. Calicó, J. Ortega (Barcelona, E) Polyomavirus (PV) and, particularly, BKV has been associated with the development of haemorrhagic cystitis (HC) in transplanted patients. It is known that PV infection is common and most frequently assymptomatic in humans and that PV can remain in latent status in the renal tissue until they become reactivated. Objectives of this study were to know the frequency of PV found in urine of patients receiving an HCT before and after transplant, the correlation with the development of HC and the possible predictive value of a PCR qualitative technique of detection. Patients and methods: A total of 59 children (ages between 3 months and 16 years, median 7 years) undergoing an HCT (allogeneic: 41, autologous: 18) were included in the study over a 18 month period (April 2000 -September 2001 . Urine samples were taken pre-transplant and at 15, 30 and 90 days posttransplant. The method for detection of BKV and JCV consisted on a multiplex nested PCR after DNA viral extraction with guanidine thyocyanate. Results: Prevalence of urinary excretion of PV before trasplant was 45% (BKV: 34%, JCV: 11%, both: 2%). After HCT, 80% of patients excreted PV (BKV: 72% and JCV:8%). Eleven patients (18,6%) (10 after allo-HCT and 1 after auto-HCT) developed an HC: grade I:1, grade II: 8 and grade III: 2. The median time to HC from HCT was 31 days (20-66).Fifty percent of the patients with HC excreted BKV before transplant and all of them become excretors after transplant. Duration of HC ranged from 8 to 90 days (median 31 days). All the patients were treated with hyperhydration, urinary alkalinization and diuretics; two patients suffered severe obstruction and required vesical lavages. Antiviral agents were not given in any case. Eigth of the eleven patients with HC had a favourable outcome; the other 3 died with HC but this was not considered the main cause of death. Conclusions: 1/ A reactivation of BKV infection after transplant was seen; the proportion of patients excreting virus increased from 34% to 72%. 2/ All patients with HC excreted BKV. 3/ The qualitative PCR method of detection of BKV was not valid for predicting the development of HC. A quantitative PCR should be used in future studies.
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Active parvovirus B19 infection in hematologic patients M. Lindauer, K. Weise, C. Huber, A. Ullmann (Mainz, D) Objective: To study the incidence of active parvovirus B19 infection in hematologic patients, all patients admitted to a hematologic ward were screened on a regular basis by PCR for a time period of 6 months. Methods: 121 samples were drawn from 56 patients, a median of 2 (1-7) per patient. Patient characteristics
